Eric S Winer

13PUBLICATIONS
72CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCardiovascular medicine and haematology not elsewhere classifiedHorticultural crop improvement (incl. selection and breeding)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|May 26, 2026
Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

|Feb 24, 2026
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

H Moses Murdock, Haesook T Kim, Katie Maurer

|Jan 26, 2026
Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Luis E Aguirre, Haesook T Kim, Hany Elmariah

|Oct 31, 2025
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

H Moses Murdock, Haesook T Kim, Katie Maurer

|Jan 28, 2025
Things (like AML salvage) go better with VEN(etoclax).

Eric S Winer, Richard M Stone

|Nov 15, 2024
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia.

Marlise R Luskin, Shai Shimony, Julia Keating

Pageof 3

Frequent Collaborators

11 joint publications

Jacqueline S Garcia

11 joint publications

Marlise R Luskin

7 joint publications

Daniel J DeAngelo

5 joint publications

Rahul Vedula